16+
Major trials tracked
Two leading GLP-1 therapies for obesity and type 2 diabetes
Semaglutide vs tirzepatide: trial pipelines compared
A side-by-side view of the semaglutide and tirzepatide clinical trial pipelines, built from live ClinicalTrials.gov data and refreshed daily. ClinicalTrials.gov lists 16+ phase 2–4 trials for semaglutide and 16+ for tirzepatide. Add up to three more drugs to widen the comparison.
semaglutide (16) vs tirzepatide (16)16 active2014–2030
semaglutidetirzepatide
'14
'16
'18
'20
'22
'24
'26
'28
'30
semaglutide
SUSTAIN™ 4P3
SUSTAIN™P3
SUSTAIN 7P3
STEP 3P3
STEP 6P3
STEP7P3
ASCEND PLUSP4
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®P3
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesP3
A Study of BGM0504 in Participants with Type 2 DiabetesP3
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseP2
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese PatientsP3
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese SubjectsP3
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 DiabetesP3
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight SubjectsP3
AMAZE 8P3
tirzepatide
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes MellitusP2
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 DiabetesP3
SURPASS-3P3
SURPASS-5P3
SURMOUNT-OSAP3
SURPASS-CN-INSP3
TREASURE-CKDP2
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesP3
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightP2
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightP3
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)P3
REIMAGINE 5P3
STOP KNEE-OAP4
STAY-LEANP4
GYMINDAP2
LOCITTP2
Upcoming readouts
10 ahead · 2 drugs
Select a trial to load its full ClinicalTrials.gov record.
Head to head
Registered phase 2–4 trial activity for each drug, computed from live ClinicalTrials.gov data.
semaglutide (Ozempic / Wegovy)GLP-1 & incretin therapies
14
Phase 3 trials
4
Actively recruiting
Jun 2027
Next phase 3 readout
tirzepatide (Mounjaro / Zepbound)GLP-1 & incretin therapies
16+
Major trials tracked
9
Phase 3 trials
2
Actively recruiting
None scheduled
Next phase 3 readout
Key trials across both drugs
Top 16 registered phase 2–4 trials across semaglutide and tirzepatide, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.
Track semaglutide and tirzepatide with ComplyRx
Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.
Individual pipelines and other comparisons
FAQ
- How do the semaglutide and tirzepatide clinical pipelines compare?
- ClinicalTrials.gov currently lists 16+ phase 2–4 trials for semaglutide and 16+ for tirzepatide. The timeline above plots both side by side and refreshes daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily. ComplyRx does not add efficacy or superiority claims; the comparison shows registered trial activity only.
- Can I add more drugs to the comparison?
- Yes. The tool above compares up to five drugs on one timeline, with PNG and PDF export. Add any competitor in the search box.